Trial Profile
Phase I/II Study to Evaluate the Efficacy and Safety of Combination Chemotherapy With Carboplatin, Bortezomib and Bevacizumab as First Line Therapy in Patients With Advanced Small Cell Lung Cancer.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Bortezomib (Primary) ; Carboplatin (Primary)
- Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Jan 2019 Status changed from completed to discontinued.
- 18 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Nov 2013 Planned end date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.